vebreltinib is a targeted therapy agent for specific gene mutations (e.g., MET exon 14 skipping mutation), primarily indicated for non-small cell lung cancer (NSCLC) and other conditions. It should not be administered casually, mainly due to its rigorous indication restrictions, potential adverse reaction risks, complex drug-drug interactions, and the requirement for individualized treatment under physician guidance.
Rigorous Indication Restrictions
vebreltinib is only indicated for patients with specific gene mutations (e.g., abnormalities in the MET gene), and eligibility for treatment must be confirmed through genetic testing. In the absence of testing or if the mutation type is non-eligible, administration may be ineffective and even exacerbate the patient's condition.
Potential Risks of Adverse Reactions
Common adverse reactions include fatigue, edema, and nausea. In severe cases, the drug may cause hepatic injury, interstitial lung disease, or cardiotoxicity. It is necessary to routinely monitor hepatic and renal function, electrocardiogram (ECG) and other indicators, and adjust the medication in a timely manner.
Special populations (e.g., patients with impaired hepatic and renal function, pregnant women) require a careful risk assessment, and the drug may be contraindicated or require dose adjustment for such groups.
Complex Drug-Drug Interactions
vebreltinib may interact with other medications (e.g., anticoagulants, antiepileptics) or food, affecting metabolism or enhancing toxicity. For example, certain drugs can inhibit the hepatic enzyme CYP3A4, leading to elevated plasma drug concentrations and an increased risk of adverse reactions.
Drug Resistance and Long-Term Management
Prolonged use of the drug may lead to the development of drug resistance. Physicians are required to dynamically evaluate the therapeutic effect and modify the treatment regimen as needed. Patients must not increase, decrease the dose or discontinue the medication without authorization, to avoid disease progression or recurrence.
Prescription Drug Requirement and Individualized Treatment
vebreltinib is a prescription drug and must be used under the guidance of an oncologist. Physicians need to formulate a treatment plan based on the patient's condition, genetic testing results and overall health status, and conduct full-course monitoring of the drug's safety and effectiveness.
All medication decisions must be based on a professional physician's diagnosis and treatment recommendations. Patients are not allowed to obtain or adjust the medication without authorization. If any discomfort or suspected adverse reactions develop, immediate medical attention should be sought.
